Jennifer Burgtorf
Primary Care · Woodhaven, MINPI 1205202025
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 143 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $934 and has fallen 91.5% since, to $80 in 2025.
Across 143 payments — averaging $15.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$505
- Novo Nordisk$499
- Pfizer$265
- Boehringer Ingelheim$225
- AbbVie$180
- GSK$110
- plus $497 from 17 others
What the payments were for
- Food & beverage$2,281100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 31 | $505 |
| Novo Nordisk | 34 | $499 |
| Pfizer | 15 | $265 |
| Boehringer Ingelheim | 12 | $225 |
| AbbVie | 13 | $180 |
| GSK | 8 | $110 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $65 |
| Amarin Pharma, Inc. | 4 | $64 |
| Bayer | 3 | $45 |
| Abbott | 2 | $44 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Exact Sciences | 2 | $32 |
| AstraZeneca | 2 | $30 |
| Merck | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $29 |
| Philips North America LLC | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Amgen | 1 | $13 |
How this compares
$2,281 in reported general payments places this provider in the 85th percentile of 292 primary care providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 46 | $49,789 |
| OzempicSemaglutide | 38 | $43,474 |
| MounjaroTirzepatide | 29 | $33,917 |
| JardianceEmpagliflozin | 28 | $29,587 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $20,297 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $11,810 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $11,381 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $11,277 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $11,151 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $6,660 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,211 |
| Atorvastatin Calcium | 295 | $4,441 |
| Losartan Potassium | 168 | $2,012 |
| Metoprolol Succinate | 94 | $1,504 |
| Lisinopril | 133 | $1,254 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $265 | $49,78946 claims |
| Novo NordiskOzempic | $499 | $43,47438 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $110 | $43,25845 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $225 | $35,79840 claims |
| Lilly USA, LLCMounjaro | $505 | $33,91729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 292 primary care providers in Michigan.
Other primary care in Woodhaven
- Donna HamillGrosse Pointe$17K
- Marie Sighe-NzokouLansing$16K
- Alexandria SchwabBay City$10K
- Amy HenryRochester Hills$10K
- Claire GebaraWaterford$9K
- Vanita RobinsonDetroit$9K
- Mary BoudreauMason$9K
- Kimberly FrazierLansing$8K
- Rachel HetznerMadison Heights$8K
- Katherine HouleMarquette$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.